Clinical Trial

Hemostemix Announces Its AI Strategy

Calgary, Alberta--(Newsfile Corp. - August 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),…

4 months ago

Pres. Trump’s Chance to Fix DEA’s Marijuana Policy Failures: Rescheduling?

DEA Administrator Terrance Cole has also signaled a tough line: "Everybody knows my stance on marijuana after 30 plus years…

4 months ago

Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025

WINNIPEG, MB / ACCESS Newswire / August 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused…

4 months ago

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

Global partnerships to help customers improve clinical and commercial efficiency and effectiveness RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif., Aug.…

4 months ago

MedWellAi, Inc Joins Trump Mobile In Engaging BrighterMD To Develop Ai-Inhanced Healthcare Telemedicine Platform, Focused On $24.46 Billion Corporate Wellness Market

CLEARWATER, Fla., Aug. 18, 2025 /PRNewswire/ -- MedWell Ai, Inc, ("Company") (OTCQB: MWAI) is pleased to confirm the collaboration and execution…

4 months ago

Society of Interventional Oncology Announces First Site Approved for Enrollment in TRIBUTE Trial

A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy WASHINGTON, D.C. /…

4 months ago

Red Light Holland Receives Initial Third-Party Psilocybin Testing Results via FDA-Compliant, DEA-Registered Partner, Irvine Labs

Initial testing results confirm psilocybin potency and process validation for potential medical grade manufacturing applicationsIrvine Labs progresses development of proprietary…

4 months ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),…

4 months ago

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy…

4 months ago